Sirnaomics Launches Phase I Clinical Trial for GalNAc Factor XI Program

Study commences following green light from the U.S. FDA for Investigational New Drug Application HONG KONG, GERMANTOWN, Md. and SUZHOU, China, April 12, 2023 /PRNewswire/ — Sirnaomics Ltd. (the “Company”, Stock Code: 2257.HK, together with its subsidiaries, the “Group” or “Sirnaomics”),…